Compare Alcon AG (ALC) vs UiPath Inc (PATH) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Alcon AG vs UiPath Inc — how do they compare? Alcon AG trades at $66.71 (market cap $32.69B), while UiPath Inc trades at $11.42 (market cap $6.04B). The key difference: Alcon AG is far larger — about 5.4× UiPath Inc's market cap, and Alcon AG pays a 0.54% dividend while UiPath Inc pays none. Which is the better fit depends on your goals.
| ALC | PATH | |
|---|---|---|
Market Cap | $32.69B | $6.04B |
Sector | Health | Technology |
52-Week High | $92.22 | $19.29 |
52-Week Low | $62.02 | $9.38 |
Enterprise Value | $36.28B | $4.81B |
Dividend Yield | 0.54% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ALC trades at $66.87, down 4.01% on the day, amid a mixed technical and fundamental backdrop. The stock exhibits a bullish technical signal overall, with moving averages supporting a positive trend, while oscillators remain neutral. Fundamentally, revenue growth is steady, reaching $10.40 billion in 2025, though net income margin compressed to 7.7%. Recent news highlights product innovation, including a collaboration with RxSight for adjustable PCIOLs, signaling ongoing R&D investment. Analyst sentiment is predominantly positive, with a consensus price target of $86.00 implying significant upside.
The outlook for ALC is cautiously optimistic, driven by new product launches and strategic partnerships that may fuel growth. However, risks include competitive pressures, macroeconomic headwinds, and margin compression. With a P/E of 40.92, the valuation appears rich relative to historical norms, requiring strong earnings delivery to justify current levels. Investors should weigh robust analyst buy ratings against execution risks and market volatility.
UiPath (PATH) trades at $11.65, down 0.51% on the day, with a bullish technical signal driven by moving averages. The company shows improving fundamentals with revenue growth from $1.43B in 2025 to a projected $1.7B in 2026 and a shift to profitability. Recent news highlights expansion in agentic AI and enterprise automation, though the stock faces competitive and execution risks.
The outlook is cautiously optimistic with a consensus price target of $13.33 suggesting 14% upside. Key opportunities include strong revenue growth and margin expansion, while risks involve intense competition and the need to sustain AI-driven adoption. Analyst sentiment is mixed with 25% buy ratings amid ongoing transformation.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Alcon AG
Alcon, headquartered in Fort Worth, Texas, is the global eyecare leader with a diverse portfolio in ophthalmology including contact lenses, eye drops, surgical equipment, and related surgical products. Novartis purchased Alcon from Nestle in 2010 and, following nine years as a Novartis subsidiary, the company was spun off as a public company in April 2019. The company reports five distinct segments: implantables (16% of revenue), consumables (31%), equipment (9%), contact lenses (27%), and ocular health (17%). The company is geographically diversified, with only about 40% of revenue from the U.S. market, and the firm has a strong presence in the European Union and Japan.
Read more on ALC →About UiPath Inc
UiPath Inc creates an end-to-end platform that provides automation with user emulation at its core. Its platform is built to be used by employees throughout a company and to address a wide variety of use cases, from simple tasks to long-running, complex business processes. It generates revenue from the sale of licenses for its proprietary software, maintenance and support, and professional services. It generates a majority of the revenues from the US, followed by Romania and the rest of the world.
Read more on PATH →
